With new RSV antibody, Sanofi looks to avoid a repeat of a 20-year-old pricing controversy
Twenty-four years ago, the FDA approved a drug as controversial as it was innovative.
Known as Synagis, it was OK’d for protecting certain infants against respiratory syncytial virus, or RSV, the leading cause of infant hospitalization in the US and Europe. It was the first antibody approved for an infectious disease, a forerunner of the antibody treatments deployed during the pandemic to treat or protect people from Covid-19.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 153,900+ biopharma pros reading Endpoints daily — and it's free.